Validation of a claims‐based algorithm to identify cases of ulcerative colitis in Japan
-
- Haruei Ogino
- Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences, Kyushu University Fukuoka Japan
-
- Hiromu Morikubo
- Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan
-
- Keita Fukaura
- Department of gastroenterology Saiseikai Futsukaichi Hospital Fukuoka Japan
-
- Tasuku Okui
- Medical information center Kyushu University Hospital Fukuoka Japan
-
- Sean Gardiner
- Inflammation and Immunology Pfizer Inc New York New York USA
-
- Naonobu Sugiyama
- Inflammation & Immunology, Medical Affairs Pfizer Japan Inc Tokyo Japan
-
- Noritoshi Yoshii
- Inflammation & Immunology, Medical Affairs Pfizer Japan Inc Tokyo Japan
-
- Tsutomu Kawaguchi
- Inflammation & Immunology, Medical Affairs Pfizer Japan Inc Tokyo Japan
-
- Haoqian Chen
- Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA
-
- Edward Nonnenmacher
- Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA
-
- Soko Setoguchi
- Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA
-
- Naoki Nakashima
- Medical information center Kyushu University Hospital Fukuoka Japan
-
- Taku Kobayashi
- Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan
書誌事項
- 公開日
- 2021-11-26
- 権利情報
-
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- DOI
-
- 10.1111/jgh.15732
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Aim</jats:title><jats:p>The prevalence of ulcerative colitis (UC) is increasing in Japan. Validated claims‐based definitions are required to investigate the epidemiology of UC and its treatment and disease course in clinical practice. This study aimed to develop a claims‐based algorithm for UC in Japan.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A committee of epidemiologists, gastroenterologists, and internal medicine physicians developed a claims‐based definition for UC, based on diagnostic codes and claims for UC treatments, procedures (cytapheresis), or surgery (postoperative claims). Claims data and medical records for a random sample of 200 cases per site at two large tertiary care academic centers in Japan were used to calculate the positive predictive value (PPV) of the algorithm for three gold standards of diagnosis, defined as physician diagnosis in the medical records, adjudicated cases, or registration in the Japanese Intractable Disease Registry (IDR).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Overall, 1139 claims‐defined UC cases were identified. Among 393 randomly sampled cases (mean age 44; 48% female), 94% had received ≥ 1 systemic treatment (immunosuppressants, tumor necrosis factor inhibitors, corticosteroids, or antidiarrheals), 7% had cytapheresis, and 7% had postoperative claims. When physician diagnosis was used as a gold standard, PPV was 90.6% (95% confidence interval [CI]: 87.7–93.5). PPV with expert adjudication was also 90.6% (95% CI: 87.7–93.5). PPVs with enrollment in the IDR as gold standard were lower at 41.5% (95% CI: 36.6–46.3) due to incomplete case registration.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The claims‐based algorithm developed for use in Japan is likely to identify UC cases with high PPV for clinical studies using administrative claims databases.</jats:p></jats:sec>
収録刊行物
-
- Journal of Gastroenterology and Hepatology
-
Journal of Gastroenterology and Hepatology 37 (3), 499-506, 2021-11-26
Wiley

